CYP2C19_2_3基因多态性_省略_氯吡格雷临床疗效相关性的系统评价_杨莉萍.pdfVIP

• 2012, 12(9): CYP2C19*2*3 1 1,2 1 1* 1. 1007302. 110016 CYP2C19*2*3 EMbasePubMedh e Cochrane Library Clinical TrialCBM CNKI CYP2C19*2*3 2011 11 2 RevMan 5.1 Meta 13 14 n=36 855Meta CYP2C19*2*3 CYP2C19*1 CYP2C19*2*3 CYP2C19*1 P0.000 11 CYP2C19*1 92% P0.000 1 CYP2C19*2*3 CYP2C19*1 CYP2C19*2*3 1 PCI CYP2C19 CYP2C19 Meta Correlation between the Genetic Polymorphism of CYP2C19*2, *3 and the Clinical Efficacy of Clopidogrel: A Systematic Review 1 1,2 1 1* YANG Li-ping , XIE Jing , LIU Yao , HU Xin 1. Department of Pharmacy, Beijing Hospital, Ministry of Public Health, Beijing 100730, China; 2. College of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China Abstract Objective To systematically evaluate anti-platelet effect of clopidogrel influenced by CYP2C19 *2, *3 polymorphism in patients with cardiovascular diseases, in order to provide references for its safe medication. Meth- ods Literature was retrieved in electronic databases covering EMbase, PubMed, h e Cochrane Library, CBM and CNKI from establishment dates to November, 2011. Observational studies and clinical trials were included, cross-checked, as- sessed and pooled for meta-analysis. meta-analysis was performed using the sot ware RevMan 5.1. Results A total of 13 articles including 14 trials (n=36 855) were included. h e results of meta-analysis showed that: a) there was no signii cant dif erence in the incidences of cardiovascular events between CYP2C19*2, *3 carriers and CYP2C19*1 carriers; b) the risk of stent thrombosis in CYP2C19*2, *3 carriers was signii cantly higher than that in CYP2C